RenovoRx, Inc.

RenovoRx, Inc. is a U.S.-based life sciences company focused on developing and commercializing targeted drug-delivery solutions for difficult-to-treat cancers. Its core product is RenovoCath, an FDA-cleared local delivery device used to deliver therapeutic agents directly to tumor sites, alongside an ongoing clinical program centered on its TAMP technology platform.

−935,9 %

70,9 %

−994,5 %

+2 511,6 %

4.02

3.93

— RenovoRx, Inc.
%
RenovoCath device sales100% Standalone sales of the RenovoCath delivery device to hospitals and cancer centers.
Clinical-stage oncology delivery platform0% Development activities tied to the TAMP platform and related clinical studies.
Registry and study-use device supply0% Device supply used in post-marketing registry and investigator-led study settings.

RenovoRx sells primarily to hospitals, cancer treatment centers, and academic oncology institutions that use RenovoCath...

  • Hospitals and cancer treatment centersprimary

    Buy RenovoCath for direct use in oncology procedures where targeted local delivery is needed.

  • Academic medical centersprimary

    Adopt the device for specialized interventional oncology cases and early clinical experience.

  • National Cancer Institute-designated centersprimary

    Use RenovoCath in advanced cancer care settings and contribute to broader clinical validation.

  • Clinical trial and registry sitessecondary

    Purchase devices for use in TIGeR-PaC and post-marketing registry studies.

RenovoRx is headquartered in the United States and its commercial activity is centered in the U.S. oncology market...

  • •United States is the core commercial market for RenovoCath
  • •U.S.-based hospitals and cancer centers are the initial customer base
  • •Medical Murray provides primary third-party manufacturing in the U.S.
  • •Commercial expansion depends on adoption across U.S. oncology centers
  • •No country-level revenue disclosure was provided in the excerpts

RenovoRx is focused on expanding RenovoCath from an early commercial launch into a broader oncology device franchise by...

01
Grow RenovoCath commercial adoptionshort-term

Recurring device sales are the main path to building a revenue base.

02
Expand clinical and real-world evidencemedium-term

Clinical familiarity and data can support broader physician adoption.

03
Maintain a capital-efficient commercial modelshort-term

A lean sales structure helps preserve resources while demand develops.

RenovoRx faces the risks typical of an early commercial medtech and life sciences company, including limited operating...

high

Limited operating history as a revenue-generating company

The company has only recently begun commercial sales, so future demand and execution are unproven.

Scope
RenovoCath commercialization
Materiality
high
high

Dependence on a single product platform

A large share of value creation depends on RenovoCath adoption and expansion into new uses.

Scope
Product concentration
Materiality
high
high

Clinical and regulatory execution risk

Clinical evidence and FDA-cleared use boundaries influence physician confidence and market expansion.

Scope
TIGeR-PaC and registry studies
Materiality
high
medium

Manufacturing and supply chain dependence

RenovoCath is produced by a primary third-party manufacturer, creating supply continuity risk.

Scope
Medical Murray, Inc.
Materiality
medium
medium

Customer adoption and repeat-order risk

Sales depend on hospitals and cancer centers integrating the device into procedures and reordering.

Scope
Hospital and oncology center customers
Materiality
medium
Revenue recognition timing
Quarterly revenue comparability
Return reserve estimation
Net sales and allowances
Fair value of common warrant liability
Net loss volatility
Classification of manufacturing costs
Gross margin and R&D expense

REGENEREX PHARMA, INC.

Pharmaceutical Preparations

Relay Therapeutics, Inc.

RLAY · Biological Products, (No Diagnostic Substances)

Revolution Medicines, Inc.

RVMD · Biological Products, (No Diagnostic Substances)

Genprex, Inc.

GNPX · Pharmaceutical Preparations

Replimune Group, Inc.

REPL · Biological Products, (No Diagnostic Substances)

Autonomix Medical, Inc.

AMIX · Surgical & Medical Instruments & Apparatus

: 29/04/2026